WAY-660222 is primarily used in scientific research for its role as a potent and selective agonist of the GPR139 receptor, a G-protein-coupled receptor expressed in the brain. It is employed to study the physiological and behavioral effects associated with GPR139 activation, particularly in relation to neurotransmitter regulation and potential neuropsychiatric disorders. Researchers utilize WAY-660222 to explore its impact on dopamine and glutamate signaling, which may provide insights into conditions such as schizophrenia, depression, and addiction. Due to its high selectivity, it serves as a valuable pharmacological tool for validating GPR139 as a therapeutic target in preclinical models. The compound is not intended for clinical use or human consumption and is restricted to laboratory research settings.